Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
Study Highlights Interim Results on Abrocitinib for Adolescents, Adults with Atopic Dermatitis
Abrocitinib shows rapid improvements in atopic dermatitis severity, maintained up to 72 weeks in patients for whom approved systemic drugs were inadequate. The JADE REAL analysis, a multicenter, open-label, expanded access protocol, evaluated 277 participants. Significant reductions in EASI, PP-NRS, %BSA, and POEM scores were observed by 72 weeks, with 78% reporting TEAEs, mostly mild or moderate.
2024 Expert Insights: More Options than Ever
2024 saw significant advancements in dermatology, with dedicated clinical trial programs for conditions like alopecia areata and chronic spontaneous urticaria. JAK inhibitors demonstrated versatility as broad-acting agents. Specific trials for subsets of diseases like hand dermatitis and genital psoriasis advanced personalized medicine. Oral roflumilast emerged as a cost-effective, broad-spectrum treatment for various inflammatory dermatoses.
Jason Hawkes, MD, MS: Looking Back on 2024, Ahead to 2025
Jason Hawkes, MD, MS, reflects on 2024 dermatology advancements, including targeted trials for under-treated conditions and versatile medications like JAK inhibitors. He highlights the shift towards personalized medicine with focus on disease subsets, and looks forward to 2025 innovations in biologics and chronic urticaria research.
Clinical utility of calcipotriene and betamethasone dipropionate for t
Cal/BD ointment, gel, foam, and cream formulations effectively treat plaque-type psoriasis, enhancing patient adherence and QoL. Cal/BD combinations offer rapid, high efficacy with minimal side effects, preventing skin atrophy and HPA axis disruption. These treatments are valuable for mild-to-moderate psoriasis, including in adolescents.
Related Clinical Trials:
BostonSight publishes pilot study on PROSE scleral lenses as a drug delivery system for ...
BostonSight published a study in *Clinical Ophthalmology* on using PROSE (scleral lenses) as a drug delivery device for preservative-free Cyclosporine 0.05% to treat dry eye disease, reporting encouraging results in symptom relief and ocular surface tolerability.
The history of uveitis: from antiquity to the present day
Uveitis, inflammation of the uveal tissues, has diverse aetiologies and contributes significantly to visual impairment. Historical descriptions from ancient civilisations through to modern times reflect evolving understanding and treatment, with advancements in immunology, diagnostics, and imaging technology. The twentieth century saw the introduction of corticosteroids and immunomodulatory agents, while the twenty-first century has seen biologics and precision medicine revolutionize treatment. Collaborative efforts and early intervention remain crucial for managing uveitis.
Macaque Lives over Six Months with Pig Kidney in Chinese Study
Chinese scientists achieved 184 days of organ function in a macaque with a gene-edited pig kidney transplant, using an improved immunosuppressive regimen. This milestone positions China competitively in xenotransplantation research, aiming for human trials.
Dry Eye Syndrome Treatment (Evaporative, Aqueous Deficient)
The Dry Eye Syndrome Treatment Market is projected to reach USD 10.13 billion by 2030, driven by increased screen use, aging population, and eye disease prevalence. Evaporative dry eye syndrome dominates due to high screen time. OTC products lead, with prescription therapies underutilized. Market challenges include product tolerability issues and regulatory hurdles. Innovations and strategic initiatives by key players, like the FDA approval of Tyrvaya nasal spray, are boosting the market. North America leads due to high disease prevalence and treatment awareness.
Dry Eye Syndrome Treatment (Evaporative, Aqueous Deficient) Market Trends
The Dry Eye Syndrome Treatment Market is projected to reach USD 10.13 billion by 2030, driven by increased screen use, aging population, and eye disease prevalence. Evaporative dry eye syndrome dominates due to high screen exposure. OTC products lead, with only 10% on prescription therapies. Innovations and new product launches by key players like Novartis, AbbVie, and Oyster Point Pharma are boosting the market.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath